Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for pharmaceutical industry professionals · Wednesday, December 19, 2018 · 471,556,187 Articles · 3+ Million Readers

Human Growth Hormone Drugs: Global Strategic Business Outlook to 2022 - Growth Concerns about Prolonged Usage of Growth Hormones

/EIN News/ -- Dublin, July 11, 2018 (GLOBE NEWSWIRE) -- The "Human Growth Hormone Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.

The report profiles 28 companies including many key and niche players such as:

  • Eli Lilly and Company (US)
  • Ferring Holding SA (Switzerland)
  • Genentech, Inc. (US)
  • GeneScience Pharmaceuticals Co., Ltd. (China)
  • Merck KGaA (Germany)
  • Novo Nordisk A/S (Denmark)
  • Pfizer, Inc. (US)
  • Sandoz International GmbH (Germany)

Key Topics Covered

1. INDUSTRY OVERVIEW
Market Outlook
Evolution of Recombinant Human Growth Hormones (hGH)
Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small
Strong Innovation Drive Takes Hold of the hGH Industry
Sizing the Market
Key Growth Drivers
High Prevalence of Growth Hormone Deficiency Disorders
Innovations Hold the Key to Market Growth
New Indications for hGH Replacement Therapy
Major Growth Restraining Factors
Complex Delivery System
High Cost of hGH Treatment
Difficulty in Securing Reimbursement
Biosimilars Threaten Revenue Growth Erosion
Limited Pharmacological Differences Exist Among Current Agents

2. MARKET TRENDS & ISSUES
Pediatric GHD Rules, while Adult GHD Remains Underserved
Long-Acting hGH Drugs
a Potential Game Changer
Select Long-Acting hGH Products in Pipeline by Development Stage
Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth
Manufacturers Bet on Novel Drug Delivery Technologies
Phase IV Studies Necessitated for First Biosimilars
Needle-less Drug Delivery Systems to Wipe Out of Syringes
Drug Delivery Device Options for Marketed hGH Products
Growing Non-Prescription/Off-Label Usage
A Potential Health Hazard
Oral hGH Secretagogues
An Alternative to Controversial hGH Injections in Professional Sports
Risk of Cancer Necessitates Judicious Use of hGH in Children
Dose Titration
A Key to Achieve Enhanced Tolerability
Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE
hGH
A Highly Consolidated Market
Overview of Select Leading Marketed hGH Products
Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
the Somatropin Biosimilar
Somatropin Biopartners
Review of Select hGH Products in Pipeline
OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market
Somavaratan Advances Further in Clinical Trials
Somapacitan Moves Ahead in Development; Nears Commercial Launch
TransCon hGH
the Potential Blockbuster hGH Product in Waiting

4. HUMAN GROWTH HORMONE: AN OVERVIEW

5. RECENT INDUSTRY ACTIVITY
NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing
Ascendis Pharma Commences Phase III Trial on TransCon hGH
Teijin Inks License Deal with Versartis for Somavaratan
JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject Liquid Formulations
Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand
EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen
Versartis Commences Phase II/III Studies for VRS-317 in Japan
Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone
Hanmi Introduces Development-Stage Long Acting hGH
Novo Nordisk Obtains FDA Approval for Norditropin FlexPro Prefilled Pen
OPKO and Pfizer Ink Agreement for Development of OPKO's Long- acting hGH-CTP
Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children

6. FOCUS ON SELECT GLOBAL PLAYERS
Eli Lilly and Company (US)
Ferring Holding SA (Switzerland)
Genentech, Inc. (US)
GeneScience Pharmaceuticals Co., Ltd. (China)
Merck KgaA (Germany)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (US)
Sandoz International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 28 (including Divisions/Subsidiaries 33)

  • The United States (10)
  • Canada (1)
  • Japan (2)
  • Europe (10)
    • Germany (4)
    • The United Kingdom (2)
    • Rest of Europe (4)
  • Asia-Pacific (Excluding Japan) (9)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/jjxgm7/human_growth?w=12

                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Endocrine and Metabolic Disorders Drugs
                    

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release